Browsing: IDH1

Treatments

Azacitidine Triplet Produces Durable MRD-Negative Remissions in IDH1+ AML

By NewsCancerJune 12, 20260

The combination of azacitidine (Vidaza), venetoclax (Venclexta), and ivosidenib (Tibsovo) produced composite complete remissions (CRc) in patients with newly diagnosed…

Diagnosis

Azacitidine Triplet Yields MRD-Negative Responses in IDH1+ AML

By NewsCancerJune 3, 20260

Combining azacitidine (Vidaza) with venetoclax (Venclexta) and ivosidenib (Tibsovo) demonstrated positive minimal residual disease (MRD)–negative responses and enduring remissions among…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Changing Chemotherapy Delivery in BCG-Unresponsive Bladder Cancer

Extending Drug Exposure Without Systemic Toxicity in NMIBC Treatment

Considering STRIDE for Child-Pugh B7 and Other Underrepresented Patients

Browsing: IDH1

Azacitidine Triplet Produces Durable MRD-Negative Remissions in IDH1+ AML

Azacitidine Triplet Yields MRD-Negative Responses in IDH1+ AML

Changing Chemotherapy Delivery in BCG-Unresponsive Bladder Cancer

Extending Drug Exposure Without Systemic Toxicity in NMIBC Treatment

Considering STRIDE for Child-Pugh B7 and Other Underrepresented Patients

How End-of-Life Doulas Help Patients Exercise Autonomy in Their Care

Changing Chemotherapy Delivery in BCG-Unresponsive Bladder Cancer

Extending Drug Exposure Without Systemic Toxicity in NMIBC Treatment

Considering STRIDE for Child-Pugh B7 and Other Underrepresented Patients

How End-of-Life Doulas Help Patients Exercise Autonomy in Their Care

Latest Post

Changing Chemotherapy Delivery in BCG-Unresponsive Bladder Cancer

Extending Drug Exposure Without Systemic Toxicity in NMIBC Treatment

Considering STRIDE for Child-Pugh B7 and Other Underrepresented Patients

Subscribe to Updates

What's Hot

Browsing: IDH1